Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors.
Journal
AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
13
11
2018
accepted:
18
01
2019
pubmed:
30
3
2019
medline:
17
3
2020
entrez:
30
3
2019
Statut:
ppublish
Résumé
DSC-MR imaging using preload, intermediate (60°) flip angle and postprocessing leakage correction has gained traction as a standard methodology. Simulations suggest that DSC-MR imaging with flip angle = 30° and no preload yields relative CBV practically equivalent to the reference standard. This study tested this hypothesis in vivo. Eighty-four patients with brain lesions were enrolled in this 3-institution study. Forty-three patients satisfied the inclusion criteria. DSC-MR imaging (3T, single-dose gadobutrol, gradient recalled-echo-EPI, TE = 20-35 ms, TR = 1.2-1.63 seconds) was performed twice for each patient, with flip angle = 30°-35° and no preload (P-), which provided preload (P+) for the subsequent intermediate flip angle = 60°. Normalized relative CBV and standardized relative CBV maps were generated, including postprocessing with contrast agent leakage correction (C+) and without (C-) contrast agent leakage correction. Contrast-enhancing lesion volume, mean relative CBV, and contrast-to-noise ratio obtained with 30°/P-/C-, 30°/P-/C+, and 60°/P+/C- were compared with 60°/P+/C+ using the Lin concordance correlation coefficient and Bland-Altman analysis. Equivalence between the 30°/P-/C+ and 60°/P+/C+ protocols and the temporal SNR for the 30°/P- and 60°/P+ DSC-MR imaging data was also determined. Compared with 60°/P+/C+, 30°/P-/C+ had closest mean standardized relative CBV ( Tumor relative CBV derived from low-flip angle, no-preload DSC-MR imaging with leakage correction is an attractive single-dose alternative to the higher dose reference standard.
Sections du résumé
BACKGROUND AND PURPOSE
DSC-MR imaging using preload, intermediate (60°) flip angle and postprocessing leakage correction has gained traction as a standard methodology. Simulations suggest that DSC-MR imaging with flip angle = 30° and no preload yields relative CBV practically equivalent to the reference standard. This study tested this hypothesis in vivo.
MATERIALS AND METHODS
Eighty-four patients with brain lesions were enrolled in this 3-institution study. Forty-three patients satisfied the inclusion criteria. DSC-MR imaging (3T, single-dose gadobutrol, gradient recalled-echo-EPI, TE = 20-35 ms, TR = 1.2-1.63 seconds) was performed twice for each patient, with flip angle = 30°-35° and no preload (P-), which provided preload (P+) for the subsequent intermediate flip angle = 60°. Normalized relative CBV and standardized relative CBV maps were generated, including postprocessing with contrast agent leakage correction (C+) and without (C-) contrast agent leakage correction. Contrast-enhancing lesion volume, mean relative CBV, and contrast-to-noise ratio obtained with 30°/P-/C-, 30°/P-/C+, and 60°/P+/C- were compared with 60°/P+/C+ using the Lin concordance correlation coefficient and Bland-Altman analysis. Equivalence between the 30°/P-/C+ and 60°/P+/C+ protocols and the temporal SNR for the 30°/P- and 60°/P+ DSC-MR imaging data was also determined.
RESULTS
Compared with 60°/P+/C+, 30°/P-/C+ had closest mean standardized relative CBV (
CONCLUSIONS
Tumor relative CBV derived from low-flip angle, no-preload DSC-MR imaging with leakage correction is an attractive single-dose alternative to the higher dose reference standard.
Identifiants
pubmed: 30923088
pii: ajnr.A6015
doi: 10.3174/ajnr.A6015
pmc: PMC6461489
mid: NIHMS1524126
doi:
Substances chimiques
Contrast Media
0
Organometallic Compounds
0
gadobutrol
1BJ477IO2L
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
626-633Subventions
Organisme : NCI NIH HHS
ID : R01 CA158079
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA220378
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA082500
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA221938
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180820
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA213158
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA176110
Pays : United States
Informations de copyright
© 2019 by American Journal of Neuroradiology.
Références
J Magn Reson Imaging. 2000 Feb;11(2):114-9
pubmed: 10713942
Radiology. 2008 Nov;249(2):601-13
pubmed: 18780827
J Magn Reson Imaging. 2004 May;19(5):546-54
pubmed: 15112303
Radiology. 2010 Aug;256(2):575-84
pubmed: 20529987
Magn Reson Med. 1999 Dec;42(6):1072-81
pubmed: 10571928
Radiology. 2002 Mar;222(3):715-21
pubmed: 11867790
J Magn Reson Imaging. 2009 Dec;30(6):1298-308
pubmed: 19937930
AJNR Am J Neuroradiol. 2018 Nov;39(11):1981-1988
pubmed: 30309842
Magn Reson Med. 2000 Jun;43(6):845-53
pubmed: 10861879
Radiology. 2015 Jun;275(3):772-82
pubmed: 25742194
Tomography. 2017 Mar;3(1):41-49
pubmed: 28584878
AJNR Am J Neuroradiol. 2004 Oct;25(9):1524-32
pubmed: 15502131
Radiology. 2008 May;247(2):490-8
pubmed: 18349315
World Neurosurg. 2015 Jul;84(1):163-72
pubmed: 25772608
AJNR Am J Neuroradiol. 2010 Jan;31(1):40-8
pubmed: 19749223
Neuro Oncol. 2015 Aug;17(8):1148-56
pubmed: 25646027
AJNR Am J Neuroradiol. 2012 Jun;33(6):1081-7
pubmed: 22322605
Magn Reson Med. 2010 Sep;64(3):907-13
pubmed: 20806381
Neuro Oncol. 2015 Sep;17(9):1188-98
pubmed: 26250565
AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21
pubmed: 14970020
Magn Reson Med. 2012 Jul;68(1):30-40
pubmed: 22114040
J Neurooncol. 2018 Jan;136(1):13-21
pubmed: 28900832
J Neurooncol. 2015 May;122(3):497-505
pubmed: 25773062
Radiology. 1994 Apr;191(1):41-51
pubmed: 8134596
Neuro Oncol. 2015 Aug;17(8):1139-47
pubmed: 25754089
AJNR Am J Neuroradiol. 2011 Feb;32(2):382-7
pubmed: 21252041
Neuro Oncol. 2014 Jun;16(6):880-8
pubmed: 24431219
AJNR Am J Neuroradiol. 2015 Sep;36(9):1654-61
pubmed: 26066626
AJNR Am J Neuroradiol. 2012 Jan;33(1):69-76
pubmed: 22095961
AJNR Am J Neuroradiol. 2018 Jun;39(6):1008-1016
pubmed: 29794239
Magn Reson Imaging Clin N Am. 2003 Aug;11(3):403-13
pubmed: 14768726
Magn Reson Imaging Clin N Am. 2016 Nov;24(4):649-670
pubmed: 27742108
AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67
pubmed: 16611779
Neuro Oncol. 2012 Jul;14(7):919-30
pubmed: 22561797
AJNR Am J Neuroradiol. 2017 Mar;38(3):478-484
pubmed: 28034995